Health Technology · Pharmaceuticals: Major · NSE: JENBURPH · data 2026-10-09
Jenburkt Pharmaceuticals Ltd
Health check: Strong (7.1/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹947.1
Market cap
₹417 cr
P/E
12.7
P/B
—
ROE
18.8%
ROCE
22.7%
Debt / equity
0.01
Dividend yield
2.19%
1-year return
-9.2%
52-week high
₹1,073.9
52-week low
₹864
Operating margin
22.4%
Growth
| Revenue (last 12 months) | ₹169 cr |
| Net profit (last 12 months) | ₹33 cr |
| Sales growth, 3 years (yearly) | 7.3% |
| Profit growth, 3 years (yearly) | 12.2% |
Similar companies
Infinium Pharmachem Ltd. (INFINIUM) · Albert David Ltd (ALBERTDAVD) · Medicamen Biotech Limited (MEDICAMEQ) · Ambalal Sarabhai Enterprises Limited (AMBALALSA) · Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JENBURPH in NSE Scanner →